Proxygen harnesses cutting-edge technology and know-how to exploit this potential, thereby redefining the borders of druggable target space. A wide-spanning ...
People also ask
Did Proxygen Inks up to $2.5 billion deal with Merck?
What are molecular glue degraders?
Apr 5, 2023 · The company has signed a licensing agreement with Merck & Co. worth more than $2.55 billion in biobucks, according to an announcement Wednesday.
Aug 31, 2020 · Proxygen is a Vienna-based startup that develops therapies against cancer and other life-threatening diseases by reprogramming the cellular ...
At Proxygen, we specialize in a completely different class of drugs, called molecular glue degraders. Instead of merely inhibiting a harmful protein's function, ...
Apr 5, 2023 · Austrian molecular glue degraders discovery and development company Proxygen and Merck, known as MSD outside the US and Canada, have entered ...
Proxygen develops innovative therapies against cancer and other life-threatening diseases by reprogramming the cellular protein quality control system.
Proxygen is a biotechnology firm specializing in protein degradation therapy for treatment of cancer and other life threatening dieseses.